Novartis 4Q10 4Q Revenues: $14.2 billion (+10%) 4Q Earnings: $2.3 billion (-2%) FY Revenues: $50.6 billion (+14%) FY Earnings: $10.0 billion (+18%) Comments: Pharma sales rose 3% for the quarter to $8.0 billion, and 7% for the year to $30.6 billion. The Sandoz generics unit was up 10% in 4Q10 to $2.4 billion and 14% for FY10 ($8.5 billion). The integration of Alcon added $1.8 billion to 4Q10 sales and $2.4 billion for FY10. The biggest growth in the pharma segment came from the On...